Having presented a strong full set of data on its PARP inhibitor Rubraca (rucaparib), Clovis Oncology Inc. once again is being mentioned as an attractive candidate to be acquired, but its chief executive Patrick Mahaffy is not listening to the rumors.
Clovis CEO Sees Rosy Future With Rubraca
Success in the ARIEL3 trial for its ovarian cancer agent and a collaboration with Bristol-Myers Squibb has put Clovis in a healthy position, CEO Patrick Mahaffy tells Scrip.
More from Anticancer
More from Therapy Areas
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.